Pitié-Salpêtrière - Charles Foix, AP-HP
Paris, Île-de-France Region, 75013, France
NCT Number: NCT04881227
Vaccine hesitancy also concerns healthcare workers (HCWs). However, HCWs are at the frontline of the COVID-19 pandemic and identified as a priority target group for COVID-19 vaccines. Thus, the identification of interventions likely to improve COVID-19 vaccine attitudes and intentions among HCWs is of interests to increase the vaccine coverage among HCWs. The study hypothesis is that the use of the same chatbot as the one tested in the general population in France could also improve the COVID-19 vaccine intentions and perceptions in HCWs.
Looking for future studies?
Notify Me18 year–99 year
All sexes
Interventional
Not applicable
Paris, Île-de-France Region, 75013, France
Most countries face the issue of vaccine hesitancy, with sizeable fractions, or sometimes the majority, of the public opposing some vaccines. The problem is particularly acute in the case of COVID-19 vaccination: first, a high uptake of COVID-19 vaccines is necessary to reach and sustain herd immunity; second, and to the best of our knowledge, no country is currently planning on making COVID-19 vaccination mandatory, making public approval essential. Unfortunately, hesitancy towards COVID-19 vaccines is high in many countries. It is therefore crucial that health authorities make it as easy as possible for people who want to be vaccinated to do so, but also that they devise communication strategies to reassure vaccine hesitant individuals. A recent study performed in France (Altay S, et al. 2021) introduced a novel messaging strategy: the use of a chatbot that answers people's questions about COVID-19 vaccines. Results suggest that a properly scripted and regularly updated chatbot could offer a powerful resource to help fight hesitancy towards COVID-19 vaccines.
Vaccine hesitancy also concerns healthcare workers (HCWs). However, HCWs are at the frontline of the COVID-19 pandemic and identified as a priority target group for COVID-19 vaccines. Thus, the identification of tools likely to improve COVID-19 vaccine attitudes and intentions among HCWs is of interests to increase the vaccine coverage among HCWs. The study hypothesis is that the use of the same chatbot as the one tested in the general population in France could also improve the COVID-19 vaccine intentions and perceptions in HCWs.
The primary objective will be to evaluate the short impact of the use of a chatbot on the evolution of the COVID-19 vaccine perceptions in HCWs.
The secondary objectives will be:
These objectives (primary and secondary) will be decline in the sub-groups of caregivers and non-caregivers.
The study population will be made up of HCWs from the ESPERES cohort. For the purposes of this study, a "healthcare worker" is defined as an individual who currently works in a setting where individuals receive healthcare (i.e. individuals do not have to work directly with patients, but may have any role within a setting where individuals receive healthcare, such as administrative office, housekeeping, food service, etc.).
It is a randomized, two-arm, open label, parallel trial. Participants will be asked to answer a new questionnaire on their COVID-19 vaccine intention and perception, 15 days after their inclusion in the ESPERES cohort. Participants in ESPERES cohort who meet the eligibility criteria for the trial evaluating the chatbot will be randomized into 2 arms: access to the chatbot (intervention group) or access to simple information (control group). Randomization will be carried out at a 1:1 ratio, on blocks of four, stratified on the caregiver/non-caregiver group and the health facility. Randomization will be done online which ensures allocation concealment. Depending on the randomization group, participants access the chatbot or simple information. They can consult them as long as they wish. Participants will be contacted immediately after the first connection to the chatbot and again 15-days later to complete questionnaires on their COVID-19 vaccine hesitancy and perception.
The statistical analyses planned in the research protocol and those responding to specific subsequent studies nested in ESPERES and validated by the scientific committee, will be performed by the pharmaco-epidemiology center (CEPHEPI), under the responsibility of Dr Candice ESTELLAT and Pr Florence TUBACH. The CEPHEPI is backed by the public health department of the hospital group Pitié-Salpêtrière - Charles Foix, AP-HP.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
This intervention will provide to participants information on COVID-19 vaccine hesitancy consisting of the possibility of accessing a long series of questions and answers online about this vaccination.
This control intervention will provide to participants a brief text decribing the way vaccines works.
Time frame: Change from baseline to immediately after intervention (experimental or control arm)
Time frame: From baseline to day 15
Time frame: From baseline to immediately after the intervention (experimental or control arm)
Time frame: From baseline to day 15 after the intervention (experimental or control arm)
Time frame: Up to 15 days
Changes in self-reported attitudes and intention towards the COVID-19 vaccines
Time frame: End of baseline questionnaire
Participants in the Chatbot intervention will be asked whether they had been able to access the chatbot, whether the Chatbot was intuitive, pleasant, frustrating, whether the information provided in the chatbot were too simple or too complicated, and whether they had unanswered questions that they wish the chatbot had addressed (free text entry).
Assistance Publique - Hôpitaux de Paris
Other
The ESPERES Prospective Cohort of Healthcare Workers in France: Study on the Impact of a Chatbot on COVID-19 Vaccine Perceptions and Intentions
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04477213
COVID-19, Coronaviridae Infections
Dubai, United Arab Emirates
View Trial DetailsNCT04646642
COVID-19, Coping Skills
Travis Air Force Base, California, United States
View Trial DetailsNCT04682561
COVID-19, Coronaviridae Infections
Toronto, Ontario, Canada
View Trial DetailsNCT04397848
Anxiety, Anxiety Disorders
Toronto, Ontario, Canada
View Trial Details